#Acalabrutinib #venetoclax #obinutuzumab #relapsed #CLL Key message: In the phase II CLL2-BAAG trial, the efficacy of measurable residual disease (MRD)-guided triple therapy comprising acalabrutinib, venetoclax, and obinutuzumab was evaluated in 45 patients with relapsed/refractory CLL. MRD was assessed by flow cytometry in peripheral blood, while ctDNA was examined by PCR. After 6 months of triple … Continue reading Acalabrutinib, venetoclax and obinutuzumab in relapsed CLL